Your browser doesn't support javascript.
loading
Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.
Li, Ze; Liu, Xue-Wei; Chi, Zhao-Cheng; Sun, Bao-Sheng; Cheng, Ying; Cheng, Long-Wei.
Afiliación
  • Li Z; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
  • Liu XW; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
  • Chi ZC; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
  • Sun BS; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
  • Cheng Y; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
  • Cheng LW; Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
PLoS One ; 10(5): e0101019, 2015.
Article en En | MEDLINE | ID: mdl-25950441
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors are useful in treating different advanced human cancers; however, their clinical efficacy varies. This study detected K-ras mutations to predict the efficacy of EGFR-TK inhibitor cetuximab treatment on Chinese patients with metastatic colorectal cancer (mCRC). A total of 87 patients with metastatic colorectal cancer were treated with cetuximab for 2-16 months, in combination with chemotherapy between August 2008 and July 2012, and tissue samples were used to detect K-ras mutations. The data showed that K-ras mutation occurred in 27/87 (31%). The objective response rates and disease control rate in K-ras wild type and mutant patients were 42% (25/60) versus 11% (3/27) (p<0.05) and 60% (36/60) versus 26% (7/27) (p<0.05), respectively. Patients with the wild-type K-ras had significantly higher median survival times and progression-free survival, than patients with mutated K-ras (21 months versus 17 months, p=0.017; 10 months versus 6 months, p=0.6). These findings suggest that a high frequency of K-ras mutations occurs in Chinese mCRC patients and that K-ras mutation is required to select patients for eligibility for cetuximab therapy. Further prospective studies using a large sample size are needed to confirm these preliminary findings.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Proteínas Proto-Oncogénicas p21(ras) / Pueblo Asiatico / Cetuximab / Mutación / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Proteínas Proto-Oncogénicas p21(ras) / Pueblo Asiatico / Cetuximab / Mutación / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos